



2024

Annual Review

Delivering Excellence *with* Simplicity





Table of Contents

CEO Introduction	1
Highlights	2
Integrated Healthcare System	3
About Us	5
Activity	6
Strategic Investment	7
Digital Transformation	9
Emergency Services	11
Heart & Vascular	13
Electrophysiology	15
Cardiac Imaging	17
Structural Heart	19
Heart Failure	21
Cardiovascular Research	23
Heart Summit	25
Oncology	27
Medical Oncology	29
Radiation Oncology	31
Surgical Oncology	33
Orthopaedics	35
Spine	37
Ophthalmology	39
Diagnostic Imaging	41
Health Screening	43
Patient Experience	45
Quality of Care	47
Continuous Improvement	49
Services & Specialties	51
Clinical Research Publications	53

Chief Executive Introduction

I would like to welcome you to the 2024 Annual Review of Mater Private Network which highlights the achievements of our staff, our consultants, the support of our Board, and the continued loyalty of our referring physicians over the last year.

At the outset I would like to thank all of our staff for a tremendous year and delivering superb results. It was a year of both consolidation and growth. We saw significant growth in our core specialties and continued growth in our Unscheduled Care channels, while at the same time delivering new infrastructure throughout the year. In 2024 we expanded our Emergency Medicine Department and Urgent Cardiac Care Department in Dublin and added a new Cath Lab and an extra Operating Theatre. Mater Private Network Cork saw development of a new Emergency Department, Urgent Cardiac Care facility, and new Intensive Care Unit with a resultant reconfiguration of our Outpatient Clinic facilities. Both centres significantly expanded our diagnostic capabilities; we now have six CT Scanners and five MRI machines across the Network, and we will see further expansion in our diagnostic capabilities in 2025. Very significantly, Mater Private Network Cork successfully launched a cardiac surgery programme in 2024.

In keeping with our ambition to deliver excellence with increasing simplicity, we became the first hospital group to roll out a full Electronic Health Record (EHR) across all facilities in 2024. This platform will form the basis of enhanced patient experience as we simplify how the patient and their families interact with us.

Mater Private Network has always been a leader in innovation, and we include a section in this report on the Cardiovascular Research Institute (CVRI) Dublin and highlight some of its advances and publications in 2024. We ended the year with 24 people fully employed in cardiology research, in a self-funded unit that continues to contribute to national development of cardiovascular medicine.

In 2025 we will continue to strive to deliver excellent patient experiences, continue to innovate and simplify the delivery of complex care, and maintain a relentless focus on excellence seen across all parts of our Network.

Yours sincerely,



John Hurley

Group Chief Executive Officer and
Consultant Cardiothoracic Surgeon



Mater Private Network 2024 Highlights

90%

HCHAPS patient
experience score

PERL (EHR)
network-wide
launch



Opening of
the NEW cardiac
catheterisation
lab suite
in Dublin

34,500+

Heart & Vascular tests,
treatments & procedures

13%

increase in Spine
tests, treatments
& procedures

NEW spinal
surgical theatre
in Dublin



NEWLY
co-located
Emergency
Department (ED) and
Urgent Cardiac Care
(UCC) facility
in Cork

€48m

Capital investment
delivered in 2024

65,000+

Oncology tests,
treatments & procedures

NEW
cardiothoracic
surgery service
and Intensive Care
Unit (ICU) in Cork



Mater Private Network An Integrated Healthcare System



Drogheda
Satellite Clinic

Consultants
& Clinicians
330+

Dedicated
Caregivers &
Support Staff
2,500+

**Northern
Cross**
Day Hospital

Liverpool
Cancer Care
Centre

Dublin
Full Service
Hospital

Cherrywood
Day Hospital

Network facilities

- 2 Full Service Hospitals
- 2 Day Hospitals
- 2 Dedicated Cancer Centres
- 6 Satellite Clinics
- 15 Main Theatres
- 7 Minor Theatres
- 2 Intensive Care Units
- 6 Cath Labs
- 5 LINACs
- 5 MRI Scanners
- 6 CT Scanners
- 3 Surgical Robots

Mater Private Network

About Us

Mater Private Network stands at the forefront of healthcare in Ireland, with 38 years' experience across a broad range of specialties and locations.

Our strength lies in our exceptional team. From leading consultants to dedicated nurses and support staff, we are united by a commitment to excellence.

Our facilities are strategically located to ensure easy access to high quality care. Our Network includes two full service hospitals in Dublin and Cork, two Day Hospitals in North and South County Dublin, advanced Radiotherapy Centres in Limerick and Liverpool (UK), and a variety of outpatient clinics and ambulatory settings.

Our People

In 2024, Mater Private Network achieved two landmark certifications that underscore our commitment to excellence in people strategy: recognition as a **Top Employer** and certification by the **Great Place to Work Institute**.

Top Employer

The Top Employer certification highlights our excellence in "people practices", recognising our ability to create a workplace environment that enables our colleagues to thrive.

This accolade reflects the strength of our approach in talent acquisition, development, and retention, as well as our ongoing focus on promoting innovation, diversity, and inclusion across all levels of the organisation.

Great Place to Work

Great Place to Work certification emphasises the strength of our organisational culture, measured by trust, engagement, and overall employee sentiment. This recognition is particularly meaningful because it reflects the voice of our colleagues, their experiences, and their pride in the work they do.

Together, these certifications illustrate how we have aligned operational excellence with a vibrant, supportive culture. They also further highlight that Mater Private Network is a purpose-driven organisation that values the direct correlation between engaged, motivated colleagues and sustainable growth in service provision.



Mater Private Network 2024 Activity

Our integrated care network facilitated approximately 288,000 tests, treatments, and procedures for patients.

288,000

Total tests, treatments, and procedures delivered in 2024

16,156

Cardiology

735

Cardiothoracic

8,598

Urgent Cardiac
Care (UCC)

8,820

Emergency
Department (ED)

4,682

Spine

4,441

Orthopaedics

32,722

Radiation
Oncology

12,601

Medical
Oncology

3,639

Haematology

22,346

Ophthalmology

123,466

Radiology

11,905

Gastroenterology

6,956

Urology

3,263

Gynaecology

2,148

Colorectal

8,996

Vascular

Mater Private Network Strategic Investment

Dublin

At Mater Private Network, we are committed to providing exceptional healthcare through continuous investment in advanced medical infrastructure. Our recent strategic investments in Dublin include a state-of-the-art cardiac catheterisation lab suite, a specialised spinal surgical theatre, an expanded Emergency Department (ED), and a new CT scanner.

These key developments reflect our dedication to pioneering medical innovation and delivering superior patient care.

In 2024, over €33 million capital investment in Dublin delivered:



NEW
cardiac
catheterisation
lab suite



NEW
spinal surgical
theatre



Expanded
Emergency
Department (ED)



NEW
CT scanner



Opening of our new cardiac catheterisation suite in Dublin

Cork

Mater Private Network Cork increased its services across Munster with significant investment in 2024. We established identity and ownership of our Radiology service, commissioned our co-located Urgent Cardiac Care (UCC) and Emergency Department (ED) facilities, opened our new outpatient consultation suites, introduced a Department of Cardiothoracic Surgery, and opened a new Intensive Care Unit (ICU). To support the Department of Cardiothoracic Surgery and ICU service, we secured INAB accreditation (ISO 15189:2022) for blood transfusion and haematology while also expanding our laboratory capabilities to provide a 24/7 service. Sustained investment in our Cork hospital is enabling us to deliver more routine and high acuity services.

In 2024, over €15 million capital investment in Cork delivered:



NEW
outpatient
consultation suites



Radiology
service investment



Co-located ED
and UCC facilities



NEW
Department of
Cardiothoracic
Surgery



NEW
Intensive Care
Unit (ICU)



Opening of our new outpatient consultation suites in Cork

Mater Private Network Digital Transformation

PERL: Our Electronic Health Record (EHR) System

What is PERL?

PERL is our new Electronic Health Record (EHR) system, designed to enhance patient care by providing our care teams with immediate and secure digital access to comprehensive health records. It facilitates seamless communication and collaboration among healthcare providers across our network. By having patient records available in this convenient system, care can be delivered to our patients in a more efficient and personalised manner.

Investment in PERL

We have invested more than €26 million into the implementation of PERL, ensuring it is fully integrated across all our locations in Ireland. This includes the establishment of a dedicated team with resources to build, launch, maintain, and optimise the system.

PERL Journey

The PERL project began in earnest in 2022. This two-year journey was dedicated to improving our patient care systems. After extensive work, PERL officially launched in Dublin on 1st September 2024, followed by network-wide launch and go-live in Cork on 1st December 2024. This milestone reflects our unwavering commitment to adopting advanced technology for better healthcare delivery.

What is Next?

Looking ahead, we will optimise PERL's capabilities to reduce documentation errors, increase efficiencies, and provide more individualised care through seamless access to health records. We will also optimise the user experience for staff which will have a continued positive impact on patient care.



1.1 million

patient records migrated
into PERL before go-live

4.8 million

patient appointments migrated
into PERL before go-live



Upgrades to patient mobile app

In 2024, our patient app underwent a series of upgrades to enhance the user experience. With the integration of PERL, the app achieved faster loading times and more efficient operations. The app's coverage also expanded to include patients in Cork, extending our support across key service regions. Since the launch of the new app, over 4,000 patients have registered as users.

Mater Private Network Emergency Services

Urgent Cardiac Care

Dublin (Open 24/7)

Our Dublin hospital is the only private hospital in Ireland to offer an Urgent Cardiac Care (UCC) service that operates 24 hours a day, 7 days a week. Patients with active cardiac symptoms can access a walk-in service that does not require an appointment or GP referral. This service is a direct pathway to cardiac expertise without delay and is consultant-delivered, which means our patients' symptoms are assessed by a consultant cardiologist. Our highly experienced sub-specialty cardiovascular teams can treat the most complex acute or chronic cardiac conditions.

Cork

With recent investments in our facilities, our UCC service in Cork is now co-located with our Emergency Department (ED) allowing rapid access to consultant-delivered care. In cases such as chest pain, where symptoms may stem from underlying causes such as cardiac issues or pneumonia, the ED and UCC teams' close collaboration ensures an efficient diagnosis and treatment plan for patients, right from their initial visit.



Celebrations at the launch of our newly co-located UCC and ED in our Cork hospital

Emergency Department

Dublin

In April, our Dublin ED doubled its capacity with the introduction of four new patient bays. As a result, we can accommodate more patients, improve treatment times, and enhance the overall experience in our ED. Alongside our facility, our emergency care team expanded with the addition of five new specialist ED nurses and consultants to ensure patients feel the benefits of expedited treatment. In tandem with the ED expansion, we now provide a dedicated pathway for assessing fracture and trauma injuries on site. This comprehensive service includes triage, initial treatment, and access to surgical and physiotherapy consultation and review.

Cork

Mater Private Network Cork also expanded its ED in September as part of a key infrastructure project across the hospital campus. This improved ED facility, and the increased capacity it affords, gives patients greater access to our ED and team of experts with consultant-delivered care and same day diagnostics.

New features, such as a dedicated GP helpline and private treatment rooms, are a significant benefit for patients across Munster seeking emergency care in the areas of general medicine, surgery, urology, pain management, spinal surgery, and orthopaedics. Increased capacity and improved facilities have the added benefit of reducing waiting lists for public hospitals and waiting times for patients, ensuring equitable access to care, based on need.



Our Emergency Department team at the opening of our additional ED bays

Mater Private Network Heart & Vascular

The benefits our patients have experienced, alongside the growth of our Heart & Vascular departments, have been significant. The comprehensive scope of services provided by Mater Private Network has established us as a national and international leader in cardiac care.

With over 50 consultants across our Heart & Vascular departments in Dublin and Cork, we now offer timely access to sub-specialty expertise at both locations. We treat the full spectrum of heart-related conditions, from routine to highly complex cases.

Mater Private Network Dublin is home to Ireland's only Complex, High-Risk Coronary Interventional Procedures (CHIP) programme, providing advanced care for high-risk patients.

Our 24/7, consultant-delivered Urgent Cardiac Care (UCC) service is unique in Ireland, offering rapid access to patients with the option to walk in at any time, day or night.

We are deeply committed to the value of research. In 2020, the Cardiovascular Research Institute (CVRI) Dublin was established. In its fourth year, it stood among Ireland's leading cardiology research institutes.



34,500+

Heart & Vascular tests, treatments,
and procedures were delivered in 2024



Our team at the opening of our new cath lab in Dublin

Developments in 2024

In 2024, we opened a state-of-the-art cardiac catheterisation laboratory (cath lab) suite at our Eccles Street hospital. Equipped with the latest imaging systems, the new suite supports both minimally invasive procedures and open-heart surgery. It also features the Medinbox system, enabling live teaching sessions and expanding our international education and training capacity.

At Mater Private Network Cork, we strengthened our consultant team with the addition of five specialist cardiologists, bringing expertise in heart failure, cardiac imaging, and interventional cardiology. Further advancing the complexity of care we provide, we also established a Department of Cardiothoracic Surgery, led by Ms. Niamh Keenan, Consultant Cardiothoracic Surgeon at Mater Private Network Cork, and supported by a new, purpose-built Intensive Care Unit (ICU).

Among our extensive heart & vascular treatment areas are:



Coronary Intervention



Structural Heart Disease



Vascular Disease



Cardiac Rhythm Disorders



Cardiac Imaging



Cardiothoracic Surgery



Ireland's Only CHIP Programme treating Complex PCI

66

Expert Consultants

5,873

Coronary Angiograms/PCI

2,932

Cardiac Rhythm Disorder Procedures

740

Cardiothoracic Surgeries

278

Vascular Surgeries

298

Structural Heart Procedures


Mater Private Network Electrophysiology

Pulsed Field Ablation (PFA) Milestone

Over 1,000 procedures using Pulsed Field Ablation (PFA) with Farapulse from Boston Scientific have now been performed in our cardiac catheterisation labs by our electrophysiology (EP) team led by Prof. Gábor Széplaki, Head of Cardiac Electrophysiology. PFA is a treatment option for patients with atrial fibrillation. The Atrial Fibrillation Institute at Mater Private Network was established in 2020 and has since grown to be the largest group of EP consultants in Ireland, treating approximately 40% of the country's patients with atrial fibrillation.

Optrell™ Mapping Catheter

Our Dublin hospital was the first in Ireland to introduce the Optrell™ Mapping Catheter in our EP laboratory. Our EP team is leveraging this cutting-edge technology to manage some of the most challenging cardiac arrhythmia cases. The Optrell™ Mapping Catheter, in conjunction with the CARTO™ 3 System, provides high-resolution directional mapping and intelligent insights, enabling our cardiologists to accurately and efficiently identify ablation targets. This innovation ensures a significant improvement in patient outcomes for the treatment of cardiac arrhythmias.



The EP team involved in the Optrell™ Mapping Catheter rollout

Assert-IQ™ Insetable Cardiac Monitor

In 2024, Mater Private Network was chosen for a limited market release of Abbott's new Assert-IQ™ Insetable Cardiac Monitor (ICM), making it the first hospital in Ireland to offer this new technology to patients. Following the first procedure carried out in our Dublin hospital, the device was rolled out across our sites in Dublin and Cork, improving the detection and treatment of arrhythmias in patients across our network. With the device's enhanced insights, clinicians can now detect premature ventricular contractions (PVCs), record if a patient became unstable or felt dizzy during an episode, track elevated heart rates with and without physical activity, and assess trends over time. Combined, the device offers a more holistic view of the patient's condition and allows for more accurate detection of arrhythmias.

Aveir™ VR Leadless Pacemaker

Our Dublin hospital was also the first private hospital in Ireland to successfully implant the Aveir™ VR Leadless Pacemaker. The Aveir™ VR Leadless Pacemaker, developed by Abbott, represents a novel approach to treating abnormal heart rhythm conditions, offering a suitable treatment option for patients who have a history of complications with conventional pacemaker systems, or patients with anticipated difficult vascular access, chronic dialysis, or high infection risk. Unlike traditional pacemakers implanted under the skin, this new device is placed directly into the heart's right ventricle via a catheter. The innovative design eliminates any visible or physical reminder of the device under the patient's skin, reduces post-implant activity restrictions, and offers a longer battery life compared to other pacemakers, thereby enhancing patient comfort and contributing to more positive treatment outcomes.



The methods by which we treat patients with routine and complex cardiac conditions are constantly evolving. It is our duty to ensure that we adopt these innovative treatments and technologies to improve patient outcomes. On several occasions, we were the first hospital network in Ireland to incorporate innovative, life-saving technologies into our treatments in 2024. We will continue this approach in the future to ensure we remain at the forefront of cardiac care for our patients.

Prof. Gábor Széplaki,
Head of Cardiac Electrophysiology

Mater Private Network Cardiac Imaging

Cardiac imaging plays a pivotal role in the effective diagnosis and treatment of conditions across all areas of our cardiology service. Our advanced imaging technology not only aids in the early detection of heart disease but also guides the planning and monitoring of treatment strategies, ensuring that patients receive the most appropriate and effective care.

The ongoing growth in our cardiovascular imaging service is driven by several key factors, including the recruitment of additional imaging cardiologists, and access to testing through connected services such as Urgent Cardiac Care (UCC). Consistent investment in our imaging infrastructure also supports fast access to scans, each of which are examined by our team of expert consultant cardiac imaging specialists. With increased demand in the last three years, we have more than doubled the number of CT coronary angiograms we have provided to patients.

This growth is expected to increase further in the coming years, bolstered by recent positive clinical trial outcomes. We have also experienced notable growth in our cardiac MRI service. The capacity of these services to handle growing patient numbers is positive and places us in a favourable position to help patients with life-changing or life-threatening cardiac conditions. Our expert team also work interoperatively as part of Ireland's only CHIP team to deliver complex procedures such as Percutaneous Coronary Intervention (PCI).



Cardiac imaging provides the critical insights our cardiologists need for accurate diagnosis and effective treatment. Growth within our service is a testament to its importance to our care teams and to our patients. Planned future investment in cardiac imaging at Mater Private Network will ensure our service remains agile to support our patients' needs.

Dr. Roger Byrne,
Head of Cardiac Imaging





Mater Private Network Structural Heart

Increasing our capacity to treat patients with structural heart conditions was a priority for the Heart & Vascular service in 2024. Building upon the work of previous years, our Structural Heart Department, led by Prof. Mark Spence, worked collaboratively with teams in areas such as cardiac imaging and heart failure to streamline identification, work-up, intervention through minimally invasive procedures, and follow-up of patients with structural heart disease.

Transcatheter Edge-to-Edge Repair

Transcatheter Edge-to-Edge Repair (TEER) was initially offered as a treatment for tricuspid valve regurgitation at Mater Private Network in 2022. Since then, we have doubled the number of patients treated using this technique. These patients require comprehensive work-up and multidisciplinary team discussion. Once a patient has been identified as suitable for TEER, they are carefully optimised pre-operatively, often making use of the expertise of our specialist heart failure service.

Throughout 2024 we also introduced the protocols and training necessary to introduce Transcatheter Tricuspid Valve Replacement (TTVR) to patients in Ireland. In 2025 we plan to build upon the success of our tricuspid TEER service with the introduction of a new treatment, EVOQUE TTVR, giving patients the opportunity to benefit from the most innovative structural heart treatments in Ireland.



In recent years, our multidisciplinary team of expert consultants and nurse specialists has worked diligently to provide essential cardiovascular care to patients across Mater Private Network. By continuing to extend our capabilities to treat structural heart disease and consistently improving our knowledge of these conditions and the patients we treat, we are well-positioned to meet the growing need for structural heart intervention in Ireland.

Prof. Mark Spence,
Head of Structural Heart





Mater Private Network

Heart Failure


At Mater Private Network, we strive to provide continuity of care for patients with long-term impaired heart function. Working closely across the multidisciplinary team, which includes a specialist heart failure nurse, the heart failure service coordinates the care pathway for individuals with advanced heart disease. It educates patients, advising on lifestyle, medication optimisation, and timely intervention with a view to improving long-term outcomes and quality of life. The complex blend of treatment options we provide to patients include opening coronary arteries, device therapy, treating patients with atrial fibrillation, and mitral and tricuspid valve clipping.

Head of Heart Failure

Recognising the importance of continuous care for patients with advanced heart disease, Mater Private Network appointed Prof. Mark Dayer as Head of Heart Failure in 2024, with a focus on consolidation and expansion of the heart failure service.

Treatments at Home

Our Heart Failure service sought to make some treatment options more accessible to patients over the last 12 months. This included establishing links with health insurance providers to offer treatment options that can be delivered at the patient's home. For some individuals, in conjunction with health insurers, we can now provide intravenous diuretics in their homes, preventing admission to hospital. Other providers can assist with optimising medical treatments, avoiding the need for repeated trips to hospital.



Looking Forward

We made significant progress in 2024 to improve this vital service and support patients living with heart failure. Our long-term goal is to significantly expand capacity and the team for this service, as over 10,000 new cases of heart failure are diagnosed in Ireland annually. With improved access to patient records and history through PERL, our process for managing each complex case will improve. This will lead to more benefits for each patient, including faster access to test results and, consequently, faster treatment.



At Mater Private Network we have made significant progress in treating patients with advanced heart disease and heart failure. Our commitment to providing treatments, including the latest mitral and tricuspid valve therapies, and collaborating with health insurers to allow some home-based diuretic services, ensures that our patients receive the highest quality care in the most convenient environments. As we look towards the future, our goal remains to harness the expertise of our specialist cardiologists and nursing teams to improve our treatments for the increasing number of individuals diagnosed with heart failure each year in Ireland.

Prof. Mark Dayer,
Head of Heart Failure

Mater Private Network Cardiovascular Research



In its fourth year, the Cardiovascular Research Institute (CVRI) Dublin continued its extraordinary trajectory of growth and development. It was an exciting year of firsts for CVRI Dublin in the areas of clinical research, Imaging Core Lab, and education.

Clinical Research

Outcomes Research

2023 outcomes research data on percutaneous coronary intervention (PCI), atrial fibrillation, and transcatheter aortic valve implantation was published in March 2024. Data collected in 2023 for PCI provided evidence that across both Dublin and Cork, event rates at discharge and one-month follow-up were found to be very low, despite the fact that 64% of lesions treated were adjudicated to be complex.

Clinical Trials

CVRI Dublin launched CYCLOPES, its first Investigator Initiated Study (IIS), sponsored by Royal College of Surgeons in Ireland, and funded by Boston Scientific. This innovative study, looking at calcium modification, will be carried out in 25 sites across seven European countries.

Prof. Gábor Széplaki and the Atrial Fibrillation Institute were chosen by Boston Scientific as one of only three centres worldwide, alongside Clinica Universidad de Navarra in Spain and Na Homolce Hospital in the Czech Republic, to participate in the NAVIGATE-PF study, examining the FARAVIEW Software Module. This is used in conjunction with the FARAWAVE Nav Pulsed Field Ablation Catheter in the treatment of patients with paroxysmal and persistent atrial fibrillation.

The Institute launched its first pharmaceutical clinical trial, HERMES, to assess the efficacy of Ziltivekimab for the treatment of patients with heart failure.

Imaging Core Lab

The Imaging Core Lab at CVRI Dublin, in an academic partnership with Radboud University Medical Centre in the Netherlands, took on the role of independent core lab for the blinded assessment of IVUS-NIRS images of the enrolled subjects of the FITTER study.



The CVRI Dublin team involved in the CYCLOPES study

This important study was presented at the European Society of Cardiology (ESC) Congress 2024 in London as a late breaking clinical trial. Dr. Himanshu Rai, Director of the Imaging Core Lab, was awarded a Fellowship of the European Society of Cardiology at the same conference.

Education

Education continues to be a key focus for CVRI Dublin. In addition to providing educational electives in partnership with RCSI University of Medicine and Health Sciences, it also disseminates information and education through the mediums of journal articles, presentations at conferences, and educational events in collaboration with industry partners such as the FARAPULSE Academy run by Prof. Széplaki, and the Dublin Cardiovascular Research Forum.

Dublin Cardiovascular Research Forum (DCRF)

In 2024, CVRI Dublin hosted 62 live sessions of the DCRF, with over 1,600 online attendances by cardiovascular health professionals from across the globe.

Live Case Broadcasts

CVRI Dublin - in partnership with Dr. Colm Hanratty, Director of Cath Lab at Mater Private Network Dublin - presented live and pre-recorded cases at international conferences including: Cardiovascular Research Foundation (CRF2024) in New York and Trans Catheter Therapeutics (TCT2024) in Washington D.C. In 2024, Mater Private Network made further investments in the Medinbox broadcasting system which is available in our new cath lab in Dublin. This investment expands the capability for international broadcasts of complex cases in our hospital.

International Publications

In 2024 CVRI Dublin continued its contribution to international research and published 47 articles in top tier, peer reviewed cardiology journals including: Nature Medicine, European Heart Journal, Journal of American College of Cardiology (JACC – Cardiovascular Interventions) and Journal of American Medical Association (JAMA). Of note was the publication of the SETANTA study findings in Scientific Reports (Nature), September 2024. This landmark study, sponsored by Mater Private Network, was the largest of its kind in Ireland. It focused on post-COVID-19 patients' cardiac health and offered insights into persistent cardiovascular symptoms, inflammation, and coagulation markers.

Study Name	Principal Investigator	Brief Study Design	Recruitment Start Date
HERMES	Prof. Mark Dayer, Dublin Dr. James Dollard, Cork	Effects of Ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.	September 2024
CYCLOPES	Dr. Colm Hanratty, Dublin	Implementation of a standardised algorithm for coronary calcification with plaque modification using ultrasound guidance to improve procedural and clinical outcomes.	September 2024
NAVIGATE-PF	Prof. Gábor Széplaki, Dublin	A study evaluating the user experience with the FARAVIEW™ technology of the RHYTHMIA HDx™ mapping system when used with the FARAWAVE NAV™ Pulsed Field Ablation Catheter in the treatment of atrial fibrillation.	May 2024
OMEGA	Prof. Ivan Casserly, Dublin	A prospective, single-arm study to assess the safety and performance of the Omega™ left atrial appendage (LAA) occluder in patients with non-valvular atrial fibrillation and high bleeding risk.	July 2024
CAPBUSTER	Dr. Colm Hanratty, Dublin	A non-randomised clinical study evaluating use of the CapBuster System Medical Device for the crossing of chronic total occlusions in coronary arteries.	May 2024

Mater Private Network

Dublin Heart Summit 2024

On Saturday, 20th April, we welcomed some of Europe's leading cardiologists to the inaugural Dublin Heart Summit to share the latest insights and pioneering advancements in cardiac care with Irish healthcare professionals, including GPs and cardiologists.

Mater Private Network, in partnership with CVRI Dublin and the Royal College of Surgeons in Ireland, hosted this event which provided a unique platform for healthcare practitioners, researchers, and stakeholders to shape the future of cardiovascular medicine and enhance patient outcomes.

The keynote address was delivered by Prof. Thomas Luscher, President-Elect of the European Society of Cardiology. Throughout the day, attendees engaged in in-depth discussions and analyses on various cardiac care topics presented by esteemed European cardiology experts. The distinguished faculty included local experts from Mater Private Network's award-winning cardiology team and international speakers such as Prof. Alan Fraiser, Dr. Maurizio Panarelli, and Prof. Borja Ibanez.

The event featured interactive sessions and dynamic discussions on the use of polypills in preventing cardiovascular disease, advancements in coronary artery disease care for women, and the evolving techniques in CT coronary angiography. Participants also explored recent regulatory changes in high-risk medical devices, interventions for tricuspid regurgitation, and atrial fibrillation. Each session concluded with engaging Q&A and panel discussions, with high levels of audience participation both online and in-person, reflecting the keen interest in these critical areas of cardiovascular medicine.

Planning and preparation for the 2025 Dublin Heart Summit began in earnest in the latter half of 2024. The event takes place at the Royal College of Surgeons in Ireland, Dublin on 12th April 2025.



Three key takeaways for Irish Healthcare Professionals:

1. The global challenge of cardiac events is being met with proactive medical and technical advancements across Europe, benefiting patients everywhere.
2. Ireland's cardiac treatment facilities rank among the best, continuously improving; early detection of heart conditions can significantly reduce mortality.
3. Cardiac disease cases are unique; excellence in patient care requires ongoing collaboration, such as our weekly multidisciplinary team meetings in Dublin and Cork, continuous learning, and insight-sharing. Events such as the Dublin Heart Summit ensure GPs and cardiologists stay up to date, better equipping them to support their patients and communities.





Our distinguished guests and presenters at the inaugural Dublin Heart Summit

Scan QR Code to watch highlights video of Dublin Heart Summit 2024



Cardiovascular disease is a leading cause of death for Irish adults and so we were honoured to bring this Heart Summit to Dublin and host it on home soil. The conference is designed to educate, spur on knowledge-share, and inspire innovation in our field, both in medical techniques and, indeed, in patient care. At Mater Private Network we are passionate about fostering a culture of international collaboration and continuous improvement, paving the way for the future of healthcare.

Prof. Robert Byrne,

Director of Cardiology at Mater Private Network, Director of CVRI Dublin, and Chair of Cardiovascular Research at Royal College of Surgeons in Ireland

Mater Private Network Oncology

Established in Dublin in 1986, the Oncology service at Mater Private Network has been providing exceptional cancer care for over 38 years. We offer leading medical, radiation, and surgical cancer treatments through our comprehensive cancer centre in Dublin, a radiotherapy centre in Limerick, and a cancer centre in Liverpool, UK. Our highly experienced consultants, supported by a multidisciplinary team of healthcare professionals, ensure that patients receive personalised care using the latest technologies and world-class expertise.

65,000+

Oncology tests, treatments, and procedures were delivered in 2024



Our ability to treat all common forms of adult cancer was bolstered in 2024 by additions to our specialist consultant teams, expansion of existing vital services, and the launch of new clinics, bringing a series of benefits to our patients. Among these are more specialist treatment options and more access points for care.

Prof. Jerome Coffey,
Head of Cancer Care



Cancer Centre

We are a founding member of **the Mater Hospitals and UCD Cancer Centre**, established in 2024. This initiative is a collaboration between Mater Private Network, Mater Misericordiae University Hospital, and University College Dublin (UCD). The vision for this centre is to improve the quality of care for our cancer patients while extending our capabilities in research and education.




The Mater Hospitals and UCD Cancer Centre

Organisation of European Cancer Institutes (OECI) Accreditation

In December 2024, the Mater Hospitals and UCD Cancer Centre began the self-assessment process to participate in the Organisation of European Cancer Institutes (OECI) Accreditation and Designation Programme.

This voluntary programme is the only cancer accreditation programme globally that evaluates comprehensive cancer care, research, and education in a singular process. Achieving OECI accreditation will ensure that our cancer centre meets and exceeds quality standards in patient representation, cancer care, and research and innovation, while bolstering our reputation as a centre of excellence throughout Europe.



Launch of the Mater Hospitals and University College Dublin Cancer Centre

Mater Private Network

Medical Oncology

Medical oncology treatments are available in our Dublin hospital and now in our day hospital located in North County Dublin (Northern Cross). Demand for medical oncology treatments at all our locations continues to rise. Our multidisciplinary cancer care teams work with patients to set an optimal treatment plan tailored to each patient's specific condition and needs.

Department Expansion

Work continued in 2024 to build upon the important progress of our medical oncology department in recent years. With the recruitment of two new consultants, we now have six full-time specialist consultants providing tailored patient treatment and guidance at our treatment sites in Dublin. Our consultant team specialises in the medical treatment of all cancers and tumour sites, including lung, breast, gynaecological, gastrointestinal, and genitourinary cancers.

New Oral Chemotherapy Clinic

Oral chemotherapy is an increasingly important treatment option for various types of cancers, including breast, colorectal, and prostate cancer. To facilitate increasing demand for this treatment, we expanded our oral chemotherapy service beyond our hospital in Eccles Street in Dublin to our day hospital in North County Dublin (Northern Cross). This new clinic, supported by two dedicated consultant oncologists and a specialist nursing team, offers a new and convenient access point to medical oncology services with the same high level of care.

16,240

Medical Oncology tests, treatments and procedures were delivered in 2024 (Dublin)

An increase of **8% year-on-year**



June
Taborada
Staff Name

Mater Private Network Radiation Oncology

Our Mid-Western Radiation Oncology Centre (MWROC) in Limerick and our Eccles Street hospital in Dublin are Mater Private Network's hubs for radiation oncology treatments. A full range of radiation oncology treatments is accessible within our network; Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), brachytherapy, Radioactive Seed Implantation (RASI), and more. With investment in the newest LINAC platform in Ireland, the Varian Halcyon, we have expanded patients' access to our renowned radiation oncology service.



PACE NODES Trial in Limerick

The Mid-Western Radiation Oncology Centre (MWROC) in Limerick participated in the PACE NODES clinical trial last year in collaboration with University Hospital Limerick (UHL). This trial utilised SBRT to treat patients with high-risk localised prostate cancer that could spread to other organs. Researchers involved in the trial will follow patient progress for at least three and a half years to determine the benefit of treating pelvic lymph nodes in addition to directly treating the prostate.

The benefit of this treatment is that it can deliver a potentially curative dose of radiation in just five sessions. Our participation in clinical trials provides our patients with a potential path to innovative treatment options. Collaboration with organisations such as UHL also creates opportunities to expand our knowledge and expertise.

Expert Implanter Programme for SpaceOAR™ Hydrogel

In 2024, Mater Private Network in Dublin became the first facility in the EMEA (Europe, Middle East, and Africa) region to be recognised as part of Boston Scientific's Expert Implanter Programme for our expertise in using SpaceOAR™ Hydrogel for prostate cancer radiation therapy. Since adopting the technology in 2019, we have performed over 850 procedures with SpaceOAR™ Hydrogel, making it an important part of the cancer care pathway. The device plays a critical role in protecting the rectum from radiation exposure, reducing the risk of harmful side effects such as bowel, urinary, and sexual health issues.

32,722

Radiation Oncology tests, treatments and procedures were delivered in 2024

An increase of **10% year-on-year**

Mater Private Network Surgical Oncology

Treating cancer with surgery is a very common intervention and is often the first line of treatment. At Mater Private Network we provide surgical interventions for cancers including breast, prostate, colorectal, and lung. The surgical treatment options we can offer to patients are ever-expanding, and this is reflected in the new services and procedures we launched in 2024.

New Head and Neck Oncology Service

We established a new head and neck oncology service with the addition of two new consultant otolaryngologists to our Eccles Street hospital in Dublin. This service is now available to patients with all types of head and neck cancers, including oral cavity, pharynx, larynx, and thyroid cancers.

Endoscopic Retrograde Cholangiopancreatography (ERCP)

Our Endoscopic Retrograde Cholangiopancreatography (ERCP) service launched in Dublin in 2024, making Mater Private Network one of the few private centres in Ireland to offer this complex, minimally invasive procedure. ERCP is used to diagnose and treat conditions affecting the bile ducts, such as bile duct stones, pancreatitis, bile duct strictures, jaundice, and tumours. Our specialist team completed approximately 50 cases between its launch in August and the end of the year.

Video Capsule Endoscopy

In December, we also launched our new video capsule endoscopy service. This procedure uses a small wireless camera contained within a capsule the size of a pill to take high-quality images of the digestive tract. It takes approximately eight hours to travel through the body, and during that time, the camera produces thousands of pictures which are used for more effective screening, diagnosis, and treatment of gastrointestinal conditions. Along with the introduction of video capsule endoscopy, our general endoscopy service is now also available six days a week.

Developments in Drogheda and Navan

Service provision at our satellite clinics in Drogheda and Navan increased in 2024. We welcomed a second consultant urologist to our team in Drogheda, improving access to our urology clinic for patients. In Navan we launched a new consultant-led colorectal clinic for patients in the region.

Both clinics are available to patients who require consultation or testing for colorectal or urological conditions which may require surgical intervention in the future. Across our services in Leinster, we now have a team of eight in-house specialist consultants who provide care from general urological conditions to robotic-assisted surgical interventions.



15,521

Surgical Oncology tests, treatments and procedures were delivered in 2024

An increase of **6% year-on-year**

Our advanced ERCP team at our Dublin hospital

Mater Private Network

Orthopaedics

Our orthopaedic services in Dublin, Cork, and Drogheda have progressed from strength to strength for several years. Patients availing of our comprehensive orthopaedic care services, encompassing foot and ankle, hip and knee, as well as shoulder, arm, and hand care, can be assured that they have access to an extensive range of support services. These include musculoskeletal imaging, pre-operative assessment clinics, physiotherapy, the new Joint Rehabilitation Programme, and 24-hour Intensive Care Unit (ICU) and Urgent Cardiac Care (UCC) support for complex cases.

Team Growth

To support the expansion of existing services and the launch of new orthopaedic services, we have been growing our consultant orthopaedic team in recent years. Since 2023, we have welcomed six new consultants, two of whom commenced practice in 2024. Each consultant brings exceptional experience and expertise, thereby enhancing the accessibility and availability of care for our patients.

New Foot & Ankle Service

Our dedicated foot and ankle orthopaedic service launched at our day hospital in North County Dublin (Northern Cross) in 2024. Through this service, patients now have fast access to comprehensive orthopaedic care for foot and ankle conditions. Treatments available within this service include minimally invasive foot and ankle surgery, ankle ligament reconstruction, bunion correction, hammertoe surgery, and treatment for heel pain, plantar fasciitis, and Achilles pathology.

Launch of Joint Rehabilitation Programme

In Dublin and Cork, we commenced the Joint Rehabilitation Programme for patients who have undergone joint replacement surgery, such as total hip and knee replacements. This new service is available to patients six weeks post-surgery and is led by our CORU-registered orthopaedic physiotherapists. The programme aims to enhance strength, range of motion, mobility, and restore pain-free functionality in the affected joint. The six-week programme is available to both pre-existing Mater Private Network post-surgery patients and patients who have had joint surgeries at other facilities.



21

Expert Consultants

1,018

Hip

745

Knee

2,678

Other

4,441

Orthopaedics tests, treatments,
and were delivered in 2024

An increase of **13% year-on-year**

Mater Private Network Spine

The enhancement of spine care at Mater Private Network remained a pivotal aspect of our strategic initiatives in 2024. Investment in new and enhanced facilities, alongside continuous innovation in the types of surgeries we offer to our patients, has positively expanded the frontiers of spine care in Ireland. Our multidisciplinary team provides a comprehensive care pathway for patients requiring both non-surgical and surgical interventions. Spine care consultation, diagnostics, and treatment are available at six locations within our network:

Dublin Eccles Street	North Co. Dublin Northern Cross	South Co. Dublin Cherrywood	Cork Citygate, Mahon	Limerick Spine Clinic	Kilkenny Spine Clinic
-------------------------	--	-----------------------------------	----------------------------	--------------------------	--------------------------

New Spinal Surgical Theatre in Dublin

In July, our new dedicated spinal surgical theatre commenced operations at our Eccles Street hospital. This project was the culmination of an €8 million investment in our Dublin facility. This new theatre has facilitated an increase in capacity for patients requiring both routine and complex surgical procedures, reduced waiting times for procedures, and extended the availability of spinal surgery in Dublin to five days a week.

This opening coincided with the release of research conducted by Mater Private Network, which revealed that almost one-third of Irish adults surveyed acknowledged suffering from back pain in their daily lives. The expanded availability of our services will have a significant positive impact on the increasing demand for spine care in Ireland.

First-of-its-kind robotic-assisted spinal surgeries in Ireland

Since 2019, Mater Private Network has been at the forefront of providing robotic-assisted spinal surgery in Ireland. In the fifth year of robotic-assisted surgery within our network, we achieved a significant milestone as Mr. Deb Roy, Consultant Spinal Surgeon at Mater Private Network Dublin, conducted two groundbreaking surgeries which were the first of their kind in the Republic of Ireland.

These procedures – extreme lateral interbody fusion and micro-access interpedicular lumbar fusion – utilised our ExcelsiusGPS™ robot. This technology enables our surgeons to make precise, small incisions, providing transformative fusion surgery with heightened accuracy and efficiency.



4,682
Spine tests, treatments, and
procedures were delivered in 2024
An increase of 12% year-on-year

1,407
Spinal Discectomy/
Decompression

1,781
Spinal Injections/
Epidural

1,006
Spinal Fusion

488
Other



2024 has been a landmark year for our Spine and Orthopaedics services in Mater Private Network. Investments in our surgical infrastructure, access points for our clinics, and in innovative robotic-assisted surgeries have been transformative. We can treat more patients, across more sub-specialties, in more locations, which is a huge positive going into 2025.

Mr. Ashley Poynton,
Clinical Director for Spine and Orthopaedics

Mater Private Network

Ophthalmology

Our ophthalmology team across the network continued to grow in 2024 with the addition of three new consultant ophthalmologists. Our network-wide team of 25 consultants are supported by a multidisciplinary team of healthcare professionals. A significant area of development in recent years has been in the treatment of glaucoma, and in 2024 we introduced another new treatment which benefits our patients.

Preserflo Microshunt Implant

The introduction of the Selective Laser Trabeculoplasty (SLT) service at Mater Private Network Dublin in 2023 brought several benefits for patients with newly diagnosed glaucoma and raised eye pressure, including lower dependence on lifelong eye drops and better control of eye pressure. In 2024, led by Mr. Pavi Agrawal, Consultant Ophthalmic Surgeon at Mater Private Network Dublin, we introduced the Preserflo Microshunt Implant service.

We were the first private hospital in Ireland to make this service available to patients. This modern technique has improved benefits for patients compared to traditional filtration surgery, such as trabeculectomy and aqueous-shunt surgery. The procedure is less invasive, has improved recovery time, and requires fewer post-operative visits to hospital. Patients throughout Ireland are now being referred to our Dublin hospital for this groundbreaking surgery.

171

Vitreotomy/Retinal Detachment

6,082

OCT

5,796

Eye Injections

22,346

Ophthalmology tests, treatments, and procedures were delivered in 2024

5,210

Cataract

1,249

YAG Laser

230

Ziemer/Laser



In recent years, the development of ophthalmology services across our network has had valuable benefits for our patients. Patients with glaucoma, for example, now have access to some of the most advanced treatments in Ireland, which is another positive step for eye health in our population. We remain committed to supporting patients across the country who require sight-saving medical and surgical intervention.

Mr. Ian Dooley,
Clinical Lead of Ophthalmology

Mater Private Network Diagnostic Imaging

Dublin

New Somatom X.cite CT Scanner

In August 2024, we unveiled a new Somatom X.cite CT scanner in our Eccles Street hospital in Dublin. We are the first hospital in Ireland to employ this advanced single-source CT scanner, underlining our commitment to providing best-in-class care to our patients. The CT room in which the equipment is housed was also fully refurbished to enhance both functionality and patient comfort. The increased efficiency of the new system will significantly reduce waiting times, allowing patients to access CT appointments within days, with reports available within 24 hours.

Cork

Radiology service update

In 2024, our Cork hospital established its identity and ownership of our radiology diagnostic services in Cork. This transition has enhanced our internal clinical capabilities, enabling us to offer a more comprehensive sub-specialty radiology service to our patients.



Our Radiology team at the launch of the Somatom X.cite CT Scanner in Dublin

34,004
X-ray

17,054
Ultrasound

7,326
Mammogram

7,573
Cardiac CT Scan

21,135
MRI

3,110
DEXA

3,246
Cardiac MRI

2,196
Interventional
Radiology

18,338
CT Scan

660
Nuclear Medicine

671
PET/CT

123,466
diagnostic scans
in 2024



2024 was another positive year for our radiology service in Dublin and across our network. With additional investment in new technologies, such as our Somatom X.cite CT scanner, our services are continually more efficient and our patients are experiencing the benefits of these improvements.

Bernard Bonroy,
Radiology Services Manager, Dublin

Mater Private Network Health Screening

HealthCheck

Access to health screening has never been more convenient at Mater Private Network. Our HealthCheck service, available at our day hospitals in North and South County Dublin, aims to help patients identify risk factors, signs, and symptoms of common conditions, which, if not detected early, could result in serious health issues.

Health Screening Options

There are a variety of health screening options available across our network. Among the most popular are AeroMedicals and Visa Medicals.

AeroMedicals: Since 2000, we have been an officially designated aeromedical centre for those wishing to obtain a licence from the Irish Aviation Authority.

Visa Medicals: We are also a designated provider of visa medicals for Australia, Canada, New Zealand, and the USA.

Other clinics and services include:

- ✓ Bone Density
- ✓ Breast Triple Assessment Clinic (TAC)
- ✓ Cancer Genetics
- ✓ Cardiac Calcium Scoring
- ✓ Cardiology Rapid Access Clinic
- ✓ Endoscopy Direct Access Clinic
- ✓ Executive Screening
- ✓ HeartCheck
- ✓ Lung Rapid Access
- ✓ Pelvic Health Clinic
- ✓ Prostate Rapid Access
- ✓ Pulmonary Function Testing
- ✓ Retinal Eye Rapid Access Clinic
- ✓ Urodynamics
- ✓ Women's Health

1,987

In 2024, there were 1,987
patient visits to HealthCheck



Mater Private Network

Patient Experience

At the core of our mission is ensuring that every patient feels heard, valued, and supported throughout their care journey. We believe that truly understanding patients' needs comes from genuine conversations – listening carefully to patients, referrers, and each other.

We collect feedback in two ways:

Qualitative

- Speaking directly to our patients and their families about their experiences in Mater Private Network care settings. We ask for their feedback across all aspects of their patient journey.

Quantitative

- Measuring through the Hospital Consumer Association for Hospital Providers Surveys (HCAHPS) – An international survey by Press Ganey (PG) tracking perceptions of hospital experience, benchmarking against large international centres of excellence. Mater Private Network is the only Irish hospital group that participates in HCAHPS.
- Measuring our Net Promoter Score (NPS) – a systematic process of measuring patient satisfaction in partnership with RedC Research.

Patient Testimonials



All the staff (medical, care assistants, breast nurse, catering, and theatre) were so professional, attentive, and kind. The food was very good. I felt I was in safe hands and received excellent care. Many thanks for your dedication and commitment to providing such care.

(Dublin)



From the moment I checked in at the reception desk to the time I left the hospital, the care & attention I got from EVERYBODY deserves a score of 10. I felt very safe there & moving through to every stage worked like clockwork. I have to say I had a very pleasant experience.

Thank you to everyone.

(Dublin)



My experience in Mater Private Network was extremely good. The nurses were very professional, very good, and caring. The team I was under and my surgeon were absolutely amazing and I was looked after so well. I am extremely happy with my results so far. I would highly recommend Mater Private Network to family and friends.

(Dublin)

Patient Satisfaction HCAHPS Press Ganey

Inpatient Experience



Outpatient Experience



Overall Patient Experience



Network-wide Net Promoter Score (NPS)

Jan to Aug inclusive:

NPS Measured from
-100 to +100



Overall Patient Satisfaction



Likely to Use Mater Private Network Again



Staff were amazing, from front of house reception to the doctor who performed the procedure and took ample time to speak to me and explain everything. I have never been treated so well in any hospital setting previously.
(Cork)



Within 2 hours of emergency referral from his GP in Kinsale, my father had been admitted into the Emergency Department. Every member of staff did their utmost to make my father's experience a positive one. The empathy and care was exemplary.
(Cork)



Very positive experience with all the staff members I dealt with. Waiting periods for treatment were short and everyone involved made a difficult time that bit easier.
(Limerick, MWROC)



Efficiency, punctuality, and words cannot do justice to the kindness, professionalism, understanding, and how accommodating the staff are.
(Limerick, MWROC)

Mater Private Network

Quality of Care

Maintaining high standards across all our care settings is the foundation upon which we provide quality care to patients. By engaging in independent and objective accreditation processes we ensure that our standards are consistently benchmarked against national and international leaders. In 2024, we continued to uphold the impeccable standards recognised in our triennial Joint Commission International accreditation process which last took place in 2023.

Joint Commission International

Mater Private Network has been accredited by Joint Commission International (JCI) to gold standard eight times since 2001 in Dublin and four times in Cork since its opening in 2013.

This accreditation provides objective assessment and recognition of the high quality of our services, patient care, and safety across all sites.

Our process to ensure that we reach this accreditation includes:

- Performance measurement, clinical audit, and benchmarking against national and international standards.
- Proactively identifying and managing risk.
- Clear accountability for quality, safety, and patient satisfaction.
- Investment in innovation, technologies, and expertise.

Some of the many achievements in 2024 include:



Irish National Accreditation Board (INAB)

- Pathology & Laboratory 16th consecutive annual accreditation.
- Cork Laboratory gained INAB ISO 15189:2022 accreditation for blood transfusion and haematology.
- Continued participation in the National QA programmes in Histopathology reporting data at a hospital and national level.



Environmental Protection Agency (EPA)

- As per the Ionising Radiation Regulations, SI 30 (2019), the EPA are the competent authority governing staff and public safety in relation to ionising radiation. One inspection was carried out by the EPA in 2024 in Radiology at Mater Private Dublin, which received a positive outcome.



Health Information Quality Authority (HIQA)

- As per the legislation SI 256 (2018), HIQA continues to be the key agency mandating the continued compliance of Mater Private Network in the delivery of care to patients in relation to all aspects of ionising radiation safety.
- HIQA carried out two onsite inspections at Mater Private Network in 2024. These occurred at our day hospital in South County Dublin (Cherrywood) and at our Mid-Western Radiation Oncology Centre, Limerick, both of which achieved a positive outcome.

Mater Private Network Continuous Improvement

Embedded within the culture of care across our network is a drive to ensure that we are consistently improving in all areas. Each year we implement strategies and highlight areas of focus which will have a lasting benefit for our patients.

Mater Private Network Clinical Care Pathway Projects

In line with the Joint Commission International (JCI) standards, these projects enable us to ensure a consistent and evidence-based healthcare journey for patients across our network.

Ares of focus in 2024 included:

1. Emergency Medicine Early Warning Score
2. Cardiothoracic surgery – pre-operative work-up
3. Scharioth Macula Lens
4. Paediatric tonsillectomies
5. Antibiotic prophylactic management

Mater Private Network Leadership Priorities 2024

Linked to the hospital leadership improvement priorities, 51 different quality improvement projects were led by departmental teams to achieve sustained improvements in processes and quality of care.



TOP PRIORITIES

1. Enhancing Patient Experience
2. PERL (EHR) focus on cyber security to protect health records
3. Empowering and engaging staff
4. Improving medication safety
5. 100% compliance with international safety goals

RepTrak Sustainability Index 2024

Mater Private Network was recognised as the second most sustainable organisation in Ireland in the RepTrak Sustainability Index 2024. This is a significant year-on-year improvement, climbing from 21st position in 2023.

This index assesses the public's perception of 100 leading organisations across key factors, including Conduct, Workplace, Social Performance, and Environmental Impact.

Our strong performance in the people-focused categories of Conduct and Social Performance reflects the Network's unwavering commitment to delivering world-class patient care while supporting staff and upholding the highest ethical standards.



BEST PRIVATE HOSPITAL

At the Private Healthcare Awards 2024, Mater Private Network received two accolades - Overall Excellence Award and the Best Private Hospital Award. The awards also reflect a range of significant achievements across the network, including the retention of Joint Commission International (JCI) Gold Standard Accreditation, a 91% customer satisfaction rating from the Voice of the Patient survey in 2023, and exemplary outcomes in patient safety metrics.

Private
Healthcare
Awards
2024



Our teams from Dublin and Cork came together to celebrate our Private Healthcare Award wins

Mater Private Network Services & Specialties

Our integrated network of care is far-reaching and provides a range of services across several specialties. These services are offered by more than 330 of Ireland's leading specialist consultants. Services and specialties include:

- ✓ Aeromedical
- ✓ Arrhythmia Clinic
- ✓ Cancer Genetics Clinic
- ✓ Cardiac Rehabilitation Programme
- ✓ Cardiac Testing
- ✓ Cardiac Transfer
- ✓ Cardiac Catheterisation Laboratories
- ✓ Central Decontamination Unit
- ✓ Complex Higher-Risk Indicated Patient Programme (CHIP)
- ✓ Day Diagnostics
- ✓ Day Oncology
- ✓ Day Procedure Unit
- ✓ Diagnostic Imaging
- ✓ Dietetics
- ✓ Emergency Department
- ✓ Gastrointestinal Lab
- ✓ Health Screening
- ✓ Heart Failure Clinic
- ✓ Joint Rehabilitation Programme
- ✓ Intensive Care Unit
- ✓ Laboratory
- ✓ Laminar Air Flow Theatres
- ✓ Outreach Clinics
- ✓ Paediatric Care
- ✓ Palliative Care
- ✓ Phlebotomy
- ✓ Physiotherapy
- ✓ Pre-Assessment Clinic
- ✓ Pulmonary Function Lab
- ✓ Radiotherapy
- ✓ Rapid & Direct Access Clinics
- ✓ Robotic Assisted Surgery
- ✓ Same Day Surgery
- ✓ Survivorship Programme
- ✓ Triple Assessment Clinic
- ✓ Urgent Cardiac Care
- ✓ Urodynamics

- ✓ Anaesthesia
- ✓ Bariatric Surgery
- ✓ Cardiology
- ✓ Cardiothoracic
- ✓ Colorectal
- ✓ Cranio/Maxillofacial
- ✓ Dental & Oral
- ✓ Dermatology
- ✓ Diabetes
- ✓ Ear, Nose & Throat
- ✓ Emergency Care
- ✓ Endocrinology
- ✓ Endoscopy
- ✓ Gastroenterology
- ✓ General Surgery
- ✓ Geriatric Medicine
- ✓ Gynaecology
- ✓ Haematology
- ✓ Histopathology
- ✓ Infectious Diseases
- ✓ Microbiology
- ✓ Nephrology
- ✓ Neurology
- ✓ Neurophysiology
- ✓ Oncology – Medical
- ✓ Oncology – Radiation
- ✓ Ophthalmology
- ✓ Orthopaedics
- ✓ Paediatrics
- ✓ Pain Management
- ✓ Palliative Care
- ✓ Pathology
- ✓ Pelvic Health
- ✓ Radiology
- ✓ Reconstructive & Aesthetic Surgery
- ✓ Respiratory Medicine
- ✓ Rheumatology
- ✓ Sleep Disorders
- ✓ Spine Surgery
- ✓ Sports Medicine
- ✓ Urogynaecology
- ✓ Urology
- ✓ Vascular
- ✓ Women's Health

Mater Private Network Clinical Research Publications

A selection of research papers published in 2024

Heart & Vascular

Use of single-chamber atrial pacemakers post-DANPACE: an analysis using national data, Scott PA, Wright IJ, Bromage DI, Plummer C, de Belder M, Dayer M, Murgatroyd FD. *Europace*. 2024 Dec 26;27(1):euae290. doi: 10.1093/europace/euae290. [Europace](#)

Operator characteristics and reintervention after pacemaker implantation: Insights from a national database, Scott PA, Cannata A, Shote A, Bromage DI, McConnachie A, Plummer C, de Belder M, Sopher M, Dayer M, McDonagh TA, Murgatroyd FD. *Heart Rhythm*. 2024 Dec 27:S1547-5271(24)03707-X. doi: 10.1016/j.hrthm.2024.12.034. Online ahead of print. [Heart Rhythm](#)

Left Ventricular Ejection Fraction Change Following Percutaneous Coronary Intervention: Correlates and Association With Prognosis, Ndrepepa G, Cassese S, Byrne RA, Bevapi B, Joner M, Sager HB, Kufner S, Xhepa E, Ibrahim T, Laugwitz KL, Schunkert H, Kastrati A. *J Am Heart Assoc*. 2024 Nov 5;13(21):e035791. doi: 10.1161/JAHA.124.035791. Epub 2024 Oct 18. [J Am Heart Assoc](#)

Endodontics and antibiotic prophylaxis?, Thornhill M, Dayer M, Lockhart P, Baddour L. *Br Dent J*. 2024 Oct;237(7):517-518. doi: 10.1038/s41415-024-7972-9. Epub 2024 Oct 11. [Br Dent J](#)

Innovation in Catheter-Directed Therapy for Intermediate-High-Risk and High-Risk Pulmonary Embolism, Zuin M, Lang I, Chopard R, Sharp ASP, Byrne RA, Rigatelli G, Piazza G. *JACC Cardiovasc Interv*. 2024 Oct 14;17(19):2259-2273. doi: 10.1016/j.jcin.2024.07.033. [JACC Cardiovasc Interv](#)

A Prospective, Randomized Trial of Bioresorbable Polymer Drug-Eluting Stents versus Fully Bioresorbable Scaffolds in Patients Undergoing Coronary Stenting, Wiebe J, Byrne RA, Bradaric C, Kuna C, Kessler T, Pfeleiderer M, Kufner S, Xhepa E, Hoppmann P, Joner M, Schunkert H, Laugwitz KL, Kastrati A, Cassese S. *J Clin Med*. 2024 Oct 7;13(19):5949. doi: 10.3390/jcm13195949. [J Clin Med](#)

Angioplasty with drug-coated balloon catheters: the coming tide?, Byrne RA, Durand R. *EuroIntervention*. 2024 Jul 1;20(13):e786-e788. doi: 10.4244/EIJ-E-24-00035. [EuroIntervention](#)

Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial, Byrne RA, Collieran R, Coughlan JJ, Jauhar R, Maillard L, De Labriolle A, Maeng M, Croft C, Brunner M, Leistner D, Zrenner B, Kollum M, Laugwitz KL, Xhepa E, Mayer K, Lahu S, Joner M, Kirtane A, Mehran R, Barakat M, Urban P, Cutlip DE, Kastrati A; COBRA-REDUCE Investigators. *Circ Cardiovasc Interv*. 2024 Oct;17(10):e013735. doi: 10.1161/CIRCINTERVENTIONS.123.013735. Epub 2024 Oct 15. [Circ Cardiovasc Interv](#)

Ten-year clinical outcomes after drug-eluting stents implantation according to clinical presentation-Insights from the DECADE cooperation, Starnecker F, Coughlan JJ, Jensen LO, Bär S, Kufner S, Brugaletta S, Räber L, Maeng M, Ortega-Paz L, Heg D, Laugwitz KL, Sabaté M, Windecker S, Kastrati A, Olesen KKW, Cassese S. *Eur J Clin Invest*. 2025 Jan;55(1):e14323. doi: 10.1111/eci.14323. Epub 2024 Oct 1. [Eur J Clin Invest](#)

Refractory inappropriate sinus tachycardia treated with pulsed field ablation of the sinus node: a breath of fresh air, Kerley RN, Fitzpatrick N, Galvin J. *Heart Rhythm*. 2024 Sep 20;S1547-5271(24)03369-1. doi: 10.1016/j.hrthm.2024.09.041. Online ahead of print. *Heart Rhythm*

Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases, Martí-Carvajal AJ, Gemmato-Valecillos MA, Monge Martín D, Dayer M, Alegría-Barrero E, De Sanctis JB, Parise Vasco JM, Riera Lizardo RJ, Nicola S, Martí-Amarista CE, Correa-Pérez A. *Cochrane Database Syst Rev*. 2024 Sep 19;9(9):CD014741. doi: 10.1002/14651858.CD014741.pub2. *Cochrane Database Syst Rev*

Symptom burden, coagulopathy and heart disease after acute SARS-CoV-2 infection in primary practice, Colleran R, Fitzgerald S, Rai H, McGovern L, Byrne RJ, Mansur A, Cradock A, Lavery R, Bisset J, McKeogh S, Cantwell G, O'Ciardha D, Wilson H, Begossi N, Blake N, Fitzgibbon M, McNulty J, Széplaki G, Heffernan E, Hannan M, O'Donnell JS, Byrne RA. *Sci Rep*. 2024 Sep 11;14(1):21229. doi: 10.1038/s41598-024-71535-8. *Sci Rep*

Commentary: Diffuse Coronary Artery Vasospasm Following Aortic Valve Replacement in a Patient With Scleroderma, Efrimescu CI, Bonnet JF, Buggy DJ. *J Cardiothorac Vasc Anesth*. 2024 Nov;38(11):2819-2822. doi: 10.1053/j.jvca.2024.07.029. Epub 2024 Jul 23. *J Cardiothorac Vasc Anesth*

Streamlining atrial fibrillation ablation management using a digitization solution, O'Brien J, Valsecchi S, Seaver F, Rosalejos L, Arellano D, Laurilla K, Jauvert G, Fitzpatrick N, Tahin T, Keelan T, Galvin J, Szeplaki G. *Eur Heart J Digit Health*. 2024 May 23;5(4):483-490. doi: 10.1093/ehjdh/ztae041. eCollection 2024 Jul. *Eur Heart J Digit Health*

An initial invasive strategy in older patients with non-ST elevation acute coronary syndromes: it is never too late, Coughlan JJ, Durand R, Byrne RA. *Eur Heart J*. 2024 Jun 14;45(23):2063-2065. doi: 10.1093/eurheartj/ehae255. *Eur Heart J*

Global Consensus Recommendations on Improving the Safety of Chronic Total Occlusion Interventions, Wu EB, Kalyanasundaram A, Brilakis ES, Mashayekhi K, Tsuchikane E; CTO Global Consensus Group. *Heart Lung Circ*. 2024 Jul;33(7):915-931. doi: 10.1016/j.hlc.2023.11.030. Epub 2024 Jun 4. *Heart Lung Circ*

Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study, Ekanem E, Neuzil P, Reichlin T, Kautzner J, van der Voort P, Jais P, Chierchia GB, Bulava A, Blaauw Y, Skala T, Fiala M, Duytschaever M, Szeplaki G, Schmidt B, Massoullie G, Neven K, Thomas O, Vijgen J, Gandjbakhch E, Scherr D, Johannessen A, Keane D, Boveda S, Maury P, García-Bolao I, Anic A, Hansen PS, Raczka F, Lepillier A, Guyomar Y, Gupta D, Van Opstal J, Defaye P, Sticherling C, Sommer P, Kucera P, Osca J, Tabrizi F, Roux A, Gramlich M, Bianchi S, Adragão P, Solimene F, Tondo C, Russo AD, Schreieck J, Luik A, Rana O, Frommeyer G, Anselme F, Kreis I, Rosso R, Metzner A, Geller L, Baldinger SH, Ferrero A, Willems S, Goette A, Mellor G, Mathew S, Szumowski L, Tilz R, Iacopino S, Jacobsen PK, George A, Osmancik P, Spitzer S, Balasubramaniam R, Parwani AS, Deneke T, Glowniak A, Rossillo A, Pürerfellner H, Duncker D, Reil P, Arentz T, Steven D, Olalla JJ, de Jong JSSG, Wakili R, Abbey S, Timo G, Asso A, Wong T, Pierre B, Ewertsen NC, Bergau L, Lozano-Granero C, Rivero M, Breitenstein A, Inkovaara J, Fareh S, Latcu DG, Linz D, Müller P, Ramos-Maqueda J, Beiert T, Themistoclakis S, Meininghaus DG, Stix G, et al. *Nat Med*. 2024 Jul;30(7):2020-2029. doi: 10.1038/s41591-024-03114-3. Epub 2024 Jul 8. *Nat Med*

Timing of multivessel revascularization in stable patients with STEMI: a systematic review and network meta-analysis, *Voll F, Kuna C, Scalamogna M, Kessler T, Kufner S, Rheude T, Sager HB, Xhepa E, Wiebe J, Joner M, Byrne RA, Schunkert H, Ndrepepa G, Stähli BE, Kastrati A, Cassese S*. *Rev Esp Cardiol (Engl Ed)*. 2025 Jan;78(2):127-137. doi: 10.1016/j.rec.2024.06.002. Epub 2024 Jun 25. *Rev Esp Cardiol (Engl Ed)*

Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel, *Aytekin A, Scalamogna M, Coughlan JJ, Lahu S, Ndrepepa G, Menichelli M, Mayer K, Wöhrle J, Bernlochner I, Witzenbichler B, Hochholzer W, Sibbing D, Angiolillo DJ, Hemetsberger R, Tölg R, Valina C, Müller A, Kufner S, Liebetrau C, Xhepa E, Hapfelmeier A, Sager HB, Joner M, Richardt G, Laugwitz KL, Neumann FJ, Schunkert H, Schüpke S, Kastrati A, Cassese S*. *Clin Res Cardiol*. 2024 Jul;113(7):1060-1069. doi: 10.1007/s00392-024-02454-x. Epub 2024 May 13. *Clin Res Cardiol*

Prevention of infective endocarditis in at-risk patients: how should dentists proceed in 2024?, *Thornhill M, Prendergast B, Dayer M, Frisby A, Lockhart P, Baddour LM*. *Br Dent J*. 2024 May;236(9):709-716. doi: 10.1038/s41415-024-7355-2. Epub 2024 May 10. *Br Dent J*

New evidence calls into question NICE's endocarditis prevention guidance, *Thornhill M, Prendergast B, Dayer M, Frisby A, Lockhart P, Baddour LM*. *Br Dent J*. 2024 May;236(9):702-708. doi: 10.1038/s41415-024-7344-5. Epub 2024 May 10. *Br Dent J*

Recent Insights Into Native Valve Infective Endocarditis: JACC Focus Seminar 4/4, *Dayer MJ, Quintero-Martinez JA, Thornhill MH, Chambers JB, Pettersson GB, Baddour LM*. *J Am Coll Cardiol*. 2024 Apr 16;83(15):1431-1443. doi: 10.1016/j.jacc.2023.12.043. *J Am Coll Cardiol*

Dual energy for pulmonary vein isolation using dual-energy focal ablation technology integrated with a three-dimensional mapping system: SmartfIRE 3-month results, *Duytschaever M, Račkauskas G, De Potter T, Hansen J, Knecht S, Philips T, Vijgen J, Scherr D, Szeplaki G, Van Herendael H, Kronborg MB, Berte B, Pürerfellner H, Lukac P*. *Europace*. 2024 May 2;26(5):euae088. doi: 10.1093/europace/euae088. *Europace*

Operator and center characteristics, and choice of pacing mode, *Scott PA, Cannata A, Shote A, Wright IJ, Bhuvana AN, Lovell MJ, Plummer C, de Belder M, Dayer M, Murgatroyd FD*. *Heart Rhythm*. 2024 Nov;21(11):2341-2343. doi: 10.1016/j.hrthm.2024.04.072. Epub 2024 Apr 23. *Heart Rhythm*

Prevalence and progression of LV dysfunction and dyssynchrony in patients with new-onset LBBB post TAVR, *Margulescu AD, Thomas DE, Awadalla M, Shah P, Khurana A, Aldalati O, Obaid DR, Chase AJ, Smith D*. *Cardiovasc Revasc Med*. 2024 Nov;68:23-29. doi: 10.1016/j.carrev.2024.04.011. Epub 2024 Apr 5. *Cardiovasc Revasc Med*

A streamlined pathway for transcatheter aortic valve implantation: The BENCHMARK study, *Frank D, Durand E, Lauck S, Muir DF, Spence M, Vasa-Nicotera M, Wood D, Saia F, Urbano-Carrillo CA, Bouchayer D, Iliescu VA, Saint Etienne C, Leclercq F, Auffret V, Asmarats L, Di Mario C, Veugeois A, Maly J, Schober A, Nombela-Franco L, Werner N, Gómez-Hospital JA, Mascherbauer J, Musumeci G, Meneveau N, Meurice T, Mahfoud F, De Marco F, Seidler T, Leuschner F, Joly P, Collet JP, Vogt F, Di Lorenzo E, Kuhn E, Disdier VP, Hachaturyan V, Lüske CM, Rakova R, Wesselink W, Kurucova J, Bramlage P, McCalmont G; BENCHMARK Investigator Group*. *Eur Heart J*. 2024 Jun 1;45(21):1904-1916. doi: 10.1093/eurheartj/ehae147. *Eur Heart J*

Trends in transcatheter aortic valve implantation practice and clinical outcomes at an Irish tertiary referral centre, *Tanner R, Giacoppo D, Saber H, Barton D, Sugrue D, Roy A, Blake G, Spence MS, Margey R, Casserly IP*. *Open Heart*. 2024 Mar 27;11(1):e002610. doi: 10.1136/openhrt-2024-002610. *Open Heart*

Cangrelor to optimise platelet inhibition in STEMI patients pre-treated with ticagrelor: A Sisyphean task?, *Coughlan JJ, Durand R, Byrne RA*. *Int J Cardiol Heart Vasc*. 2024 Feb 6;50:101355. doi: 10.1016/j.ijcha.2024.101355. eCollection 2024 Feb. *Int J Cardiol Heart Vasc*

Long-term results of ablation index guided atrial fibrillation ablation: insights after 5+ years of follow-up from the MPH AF Ablation Registry, *Fitzpatrick N, Herczeg S, Hong K, Seaver F, Rosales L, Boles U, Jauvert G, Keelan E, O'Brien J, Tahin T, Galvin J, Széplaki G*. *Front Cardiovasc Med*. 2024 Jan 16;10:1332868. doi: 10.3389/fcvm.2023.1332868. eCollection 2023. *Front Cardiovasc Med*

Anomalous origin of the left circumflex coronary artery: is surgery required? A case report, *Murray W, Lavery R, O'Brien J*. *Eur Heart J Case Rep*. 2023 Dec 23;8(1):ytad641. doi: 10.1093/ehjcr/ytad641. eCollection 2024 Jan. *Eur Heart J Case Rep*

Anaemia in patients with cardiogenic shock complicating acute myocardial infarction: Surrogate marker of poor outcome or therapeutic target?, *Coughlan JJ, Rossello X*. *Eur J Heart Fail*. 2024 Feb;26(2):458-459. doi: 10.1002/ejhf.3135. Epub 2024 Jan 21. *Eur J Heart Fail*

ACS encompasses a spectrum-unstable angina, NSTEMI, and STEMI, *Ibanez B, Byrne R*. *Eur Heart J Acute Cardiovasc Care*. 2024 Feb 9;13(1):187. doi: 10.1093/ehjacc/zuae001. *Eur Heart J Acute Cardiovasc Care*

The '10 commandments' for the 2023 ESC Guidelines for the management of acute coronary syndromes, *Byrne R, Coughlan JJ, Rossello X, Ibanez B*. *Eur Heart J*. 2024 Apr 7;45(14):1193-1195. doi: 10.1093/eurheartj/ehad863. *Eur Heart J*

Cholesterol crystals at the culprit lesion in patients with acute coronary syndrome are associated with worse cardiovascular outcomes at two years follow up - results from the translational OPTICO-ACS study program, *Nelles G, Abdelwahed YS, Seppelt C, Meteva D, Stähli BE, Rai H, Seegers LM, Sieronski L, Musfeldt J, Gerhardt T, Riedel M, Skurk C, Haghikia A, Sinning D, Dreger H, Knebel F, Trippel TD, Krisper M, Klotsche J, Joner M, Landmesser U, Leistner DM*. *Int J Cardiol*. 2024 Mar 15;399:131665. doi: 10.1016/j.ijcard.2023.131665. Epub 2023 Dec 22. *Int J Cardiol*

Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD consortium, *Siontis GCM, Coles B, Häner JD, McGovern L, Bartkowiak J, Coughlan JJ, Spirito A, Galea R, Haeblerlin A, Praz F, Tomii D, Melvin T, Frenk A, Byrne RA, Fraser AG, Windecker S; CORE-MD Investigators*. *Eur Heart J*. 2024 Jan 14;45(3):161-177. doi: 10.1093/eurheartj/ehad567. *Eur Heart J*

Type of evidence supporting ACC/AHA and ESC clinical practice guidelines for acute coronary syndrome, *Gonzalez-Del-Hoyo M, Mas-Llado C, Blaya-Peña L, Siquier-Padilla J, Coughlan JJ, Peral V, Rossello X*. *Clin Res Cardiol*. 2024 Apr;113(4):546-560. doi: 10.1007/s00392-023-02262-9. Epub 2023 Jul 12. *Clin Res Cardiol*

Coronary microevaginations characterize culprit plaques and their inflammatory microenvironment in a subtype of acute coronary syndrome with intact fibrous cap: results from the prospective translational OPTICO-ACS study, *Seppelt C, Abdelwahed YS, Meteva D, Nelles G, Stähli BE, Erbay A, Kränkel N, Sieronski L, Skurk C, Haghikia A, Sinning D, Dreger H, Knebel F, Trippel TD, Krisper M, Gerhardt T, Rai H, Klotsche J, Joner M, Landmesser U, Leistner DM*. *Eur Heart J Cardiovasc Imaging*. 2024 Jan 29;25(2):175-184. doi: 10.1093/ehjci/jead154. *Eur Heart J Cardiovasc Imaging*

A systematic assessment of the characteristics of randomized controlled trials cited by acute coronary syndrome clinical practice guidelines, *Gonzalez-Del-Hoyo M, Mas-Llado C, Siquier-Padilla J, Blaya-Peña L, Coughlan JJ, Peral V, Rossello X.* Eur Heart J Qual Care Clin Outcomes. 2024 Mar 1;10(2):176-188. doi: 10.1093/ehjqcco/qcad034. Eur Heart J Qual Care Clin Outcomes

Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study, *Armario X, Carron J, Simpkin AJ, Elhadi M, Kennedy C, Abdel-Wahab M, Bleiziffer S, Lefèvre T, Wolf A, Pilgrim T, Villablanca PA, Blackman DJ, Van Mieghem NM, Hengstenberg C, Swaans MJ, Prendergast BD, Patterson T, Barbanti M, Webb JG, Behan M, Resar J, Chen M, Hildick-Smith D, Spence MS, Zweiker D, Bagur R, Teles R, Ribichini FL, Jagielak D, Park DW, Kornowski R, Wykrzykowska JJ, Bunc M, Estévez-Loureiro R, Poon K, Götberg M, Jeger RV, Ince H, Packer EJS, Angelillis M, Nombela-Franco L, Guo Y, Savontaus M, Al-Moghairi AM, Parasca CA, Kliger C, Roy D, Molnár L, Silva M, White J, Yamamoto M, Carrilho-Ferreira P, Toggweiler S, Voudris V, Ohno Y, Rodrigues I, Parma R, Ojeda S, Toutouzas K, Regueiro A, Grygier M, AlMerri K, Cruz-González I, Fridrich V, de la Torre Hernández JM, Noble S, Kala P, Asmarats L, Kurt IH, Bosmans J, Erglis M, Casserly I, Iskandarani D, Bhindi R, Kefer J, Yin WH, Rosseel L, Kim HS, O'Connor S, Hellig F, Szejfman M, Mendiz O, Pineda AM, Seth A, Pillaha E, de Brito FS Jr, Bajoras V, Balghith MA, Lee M, Eid-Lidt G, Vandelloo B, Vaz VD, Alasnag M, Ussia GP, Tay E, Mayol J, Gunasekaran S, Sardella G, Buddhari W, Kao HL, et al.* JACC Cardiovasc Interv. 2024 Feb 12;17(3):374-387. doi: 10.1016/j.jcin.2023.10.041. Epub 2024 Jan 3. JACC Cardiovasc Interv

Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial, *Mensink FB, Los J, Oemrawsingh RM, von Birgelen C, Ijsselmuiden A, Meuwissen M, Cheng JM, van Wijk DF, Smits PC, Paradies V, van der Heijden DJ, Rai H, Ten Cate TJ, Camaro C, Damman P, van Nunen LX, Dimitriu-Leen AC, van Wely MH, Cetinyurek-Yavuz A, Byrne RA, van Royen N, van Geuns RM.* Heliyon. 2024 Sep 18;10(19):e38077. doi: 10.1016/j.heliyon.2024.e38077. eCollection 2024 Oct 15. Heliyon

EJPC @ a glance: focus issue on cardiac rehabilitation and education in preventive cardiology, *Papakonstantinou PE, Aboyans V.* Eur J Prev Cardiol. 2024 Nov 18;31(16):1901-1903. doi: 10.1093/eurjpc/zwae324. Eur J Prev Cardiol

Oncology

Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO, *Kelly CM, Bennett KE, Cahir C, Eisen A, Pusztai L.* JCO Oncol Pract. 2024 Nov 12:OP2400502. doi: 10.1200/OP-24-00502. Online ahead of print. JCO Oncol Pract

Editorial penile cancer – Super-regional centres, *Hegarty PK.* Surgeon. 2024 Oct;22(5):290-291. doi: 10.1016/j.surge.2024.06.003. Epub 2024 Jul 5. Surgeon

The use of master protocols for efficient trial design to evaluate radiotherapy interventions: a systematic review, *Gilbert A, Samuel R, Cagney D, Sebag-Montefiore D, Brown J, Brown SR.* J Natl Cancer Inst. 2024 Aug 1;116(8):1220-1229. doi: 10.1093/jnci/djae084. J Natl Cancer Inst

Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy, O'Reilly D, Farooq AR, Nevins Selvadurai P, Sheehan L, Molan K, Krishnanivas B, Mullen V, McMahon D, Hadi D, Ahmed A, Jennings M, Carroll H, Chew S, Macanovic B, O'Hanlon Brown C, Noonan SA, O'Reilly S, Connolly RM, Cahir C, Kelly CM. *Oncologist*. 2024 Oct 3;29(10):842-849. doi: 10.1093/oncolo/oyae146. *Oncologist*

Lung sparing in MR-guided non-adaptive SBRT treatment of peripheral lung tumors, Lee HY, Lee G, Ferguson D, Hsu SH, Hu YH, Huynh E, Sudhyadhom A, Williams CL, Cagney DN, Fitzgerald KJ, Kann BH, Kozono D, Leeman JE, Mak RH, Han Z. *Biomed Phys Eng Express*. 2024 Jun 20;10(4). doi: 10.1088/2057-1976/ad567d. *Biomed Phys Eng Express*

Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART), Lee G, Han Z, Huynh E, Tjong MC, Cagney DN, Huynh MA, Kann BH, Kozono D, Leeman JE, Singer L, Williams CL, Mak RH. *Radiother Oncol*. 2024 Jan;190:110034. doi: 10.1016/j.radonc.2023.110034. Epub 2023 Nov 27. *Radiother Oncol*

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B, Marmé F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, García-Sáenz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnani M, Makris A, Bassy M, Zhang Z, Furlanetto J, Nekljudova V, Loibl S. *ESMO Open*. 2024 Jun;9(6):103466. doi: 10.1016/j.esmoop.2024.103466. Epub 2024 Jun 4. *ESMO Open*

Patient-reported outcomes in high-risk HR+ /HER2 – early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE(B) study, García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, Martin M, Kelly CM, Reimer T, Toi M, Law E, Bhattacharyya H, Gnani M, Makris A, Seiler S, Burchardi N, Nekljudova V, Loibl S, Rugo HS. *Eur J Cancer*. 2024 Jan;196:113420. doi: 10.1016/j.ejca.2023.113420. Epub 2023 Nov 5. *Eur J Cancer*

The use of master protocols for efficient trial design to evaluate radiotherapy interventions: a systematic review, Alexandra Gilbert 1 2, Robert Samuel 1, Daniel Cagney 3 4, David Sebag-Montefiore 1 2, Julia Brown 2, Sarah R Brown 2, Gilbert A, Samuel R, Cagney D, Sebag-Montefiore D, Brown J, Brown SR. *J Natl Cancer Inst*. 2024 Aug 1;116(8):1220-1229. doi: 10.1093/jnci/djae084. PMID: 38720568; PMCID: PMC11308198. *JNCI*

Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO, Catherine M Kelly 1, Kathleen E Bennett 2, Caitriona Cahir 2, Andrea Eisen 3 4, Lajos Pusztai 5, Kelly CM, Bennett KE, Cahir C, Eisen A, Pusztai L. *JCO Oncol Pract*. 2024 Nov 12:OP2400502. doi: 10.1200/OP-24-00502. Epub ahead of print. PMID: 39531598. *JCO Oncology Practice*

Lung sparing in MR-guided non-adaptive SBRT treatment of peripheral lung tumors, Ho Young Lee 1, Grace Lee 1, Dianne Ferguson 1, Shu-Hui Hsu 1, Yue-Houng Hu 1, Elizabeth Huynh 2, Atchar Sudhyadhom 1, Christopher L Williams 1, Daniel N Cagney 3, Kelly J Fitzgerald 1, Benjamin H Kann 1, David Kozono 1, Jonathan E Leeman 1, Raymond H Mak 1, Zhaohui Han 1, Lee HY, Lee G, Ferguson D, Hsu SH, Hu YH, Huynh E, Sudhyadhom A, Williams CL, Cagney DN, Fitzgerald KJ, Kann BH, Kozono D, Leeman JE, Mak RH, Han Z. *Biomed Phys Eng Express*. 2024 Jun 20;10(4). doi: 10.1088/2057-1976/ad567d. PMID: 38861951. *Biomed. Phys. Eng. Express*

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B, F Marmé 1, M Martin 2, M Untch 3, C Thode 4, H Bonnefoi 5, S-B Kim 6, H Bear 7, N Mc Carthy 8, K Gelmon 9, J A García-Sáenz 10, C M Kelly 11, T Reimer 12, O Valota 13, M Toi 14, H S Rugo 15, M Gnant 16, A Makris 17, M Bassy 4, Z Zhang 18, J Furlanetto 19, V Nekljudova 19, S Loibl 20, Marmé F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, García-Sáenz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnant M, Makris A, Bassy M, Zhang Z, Furlanetto J, Nekljudova V, Loibl S. *ESMO Open*. 2024 Jun;9(6):103466. doi: 10.1016/j.esmoop.2024.103466. Epub 2024 Jun 4. PMID: 38838498; PMCID: PMC11190462. *ESMO Open*

Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy, David O'Reilly 1 2, Abdul Rehman Farooq 1, Paul Nevins Selvadurai 3, Laura Sheehan 1, Karen Molan 1, Bindu Krishnanivas 3, Valerie Mullen 3, David McMahon 1, Danial Hadi 1, Ahmed Ahmed 4, Maeve Jennings 1, Hailey Carroll 3, Sonya Chew 5, Bojan Macanovic 1, Ciara O'Hanlon Brown 6, Sinéad A Noonan 1 4, Seamus O Reilly 1, Roisin M Connolly 1, Caitriona Cahir 7, Catherine M Kelly 8, O'Reilly D, Farooq AR, Nevins Selvadurai P, Sheehan L, Molan K, Krishnanivas B, Mullen V, McMahon D, Hadi D, Ahmed A, Jennings M, Carroll H, Chew S, Macanovic B, O'Hanlon Brown C, Noonan SA, O Reilly S, Connolly RM, Cahir C, Kelly CM. *Oncologist*. 2024 Oct 3;29(10):842-849. doi: 10.1093/oncolo/oyae146. PMID: 38906704; PMCID: PMC11448882. *The Oncologist*

Final analysis of the ALTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)], de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. *ESMO Open*. 2024 Nov;9(11):103938. doi: 10.1016/j.esmoop.2024.103938. Epub 2024 Oct 17. *ESMO Open*

Smoking Cessation Support: A Marathon, Not a Sprint; The Perspectives of Cancer Patients Who Smoke, Fox P, Bhardwaj N, Lyons A, Niranjana V, Frazer K, Syed S, McCann A, Brennan S, Brennan D, Kelly C, Keane M, Fitzpatrick P. *Semin Oncol Nurs*. 2024 Apr;40(2):151584. doi: 10.1016/j.soncn.2024.151584. Epub 2024 Feb 1. *Semin Oncol Nurs*

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer, Matteo Dugo 1, Chiun-Sheng Huang 2, Daniel Egle 3, Begoña Bermejo 4, Claudio Zamagni 5, Robert S Seitz 6, Tyler J Nielsen 6, Marc Thill 7, Antonio Antón-Torres 8, Stefania Russo 9, Eva Maria Ciruelos 10, Brock L Schweitzer 6, Douglas T Ross 6, Barbara Galbardi 1, Richard Greil 11, Vladimir Semiglazov 12, Balázs Gyorffy 13 14 15, Marco Colleoni 16, Catherine M Kelly 17, Gabriella Mariani 18, Lucia Del Mastro 19, Olivia Blasi 16, Maurizio Callari 20, Lajos Pusztai 21, Pinuccia Valagussa 20, Giuseppe Viale 16, Luca Gianni # 20, Giampaolo Bianchini # 1 22, Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. *Clin Cancer Res*. 2024 Nov 1;30(21):4900-4909. doi: 10.1158/1078-0432.CCR-24-0149. PMID: 39308141; PMCID: PMC11528202. *Clin Cancer Res*

Ophthalmology

Outliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners, Ponsioen T, Hashimoto Y, Invernizzi A, Gabrielle PH, Lavid FJ, Mehta H, Silva R, Jaross N, Squirrell D, O'Toole L, Kusenda P, Barthelmes D, Gillies M, Hunt A. *Clin Exp Ophthalmol*. 2024 Dec 28. doi: 10.1111/ceo.14490. Online ahead of print. *Clin Exp Ophthalmol*

Impact of cataract surgery on patients receiving intravitreal therapy for retinal vein occlusion, Invernizzi A, Airdi M, Cozzi M, Nguyen V, Hashimoto Y, Barthelmes D, O'Toole L, Ponsioen TL, Kusenda P, Lavid FJ, Jaross N, Gillies M, Hunt A. *Clin Exp Ophthalmol*. 2024 Dec 5. doi: 10.1111/ceo.14468. Online ahead of print. *Clin Exp Ophthalmol*

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice, Deboudeau E, Beylerian H, Nguyen V, Barthelmes D, Gillies M, Gabrielle PH, Vujosevic S, Otoole L, Puzo M, Creuzot-Garcher C, Wolff B, Daien V; Fight Retinal Blindness! Study Group. *Ophthalmol Ther*. 2024 Sep;13(9):2343-2355. doi: 10.1007/s40123-024-00983-2. Epub 2024 Jul 8. *Ophthalmol Ther*

Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!, Alforja S, Hunt A, Nguyen V, O'Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J; Fight Retinal Blindness (FRB) users group. *Ophthalmol Retina*. 2024 Oct;8(10):962-970. doi: 10.1016/j.oret.2024.04.014. Epub 2024 Apr 18. *Ophthalmol Retina*

One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry, Mehta H, Gabrielle PH, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, Kheir WJ, Kok G, Vujosevic S, O'Toole L, Mangelschots E, Jaross N, Ceklic L, Daien V, Viola F, Squirrell D, Lavid FJ, Creuzot-Garcher C, Barthelmes D, Gillies M; Fight Retinal Blindness! Study Group. *Ophthalmol Retina*. 2024 Sep;8(9):872-879. doi: 10.1016/j.oret.2024.04.008. Epub 2024 Apr 16. *Ophthalmol Retina*

European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice: Data from the Fight Retinal Blindness! Registry, Boudousq C, Nguyen V, Hunt A, Gillies M, Zarranz-Ventura J, O'Toole L, Mangelschots E, Kusenda P, Schmidt-Erfurdt U, Pollreis A, Kheir WJ, Arruabarrena C, Vujosevic S, Barthelmes D, Creuzot-Garcher C, Gabrielle PH. *Ophthalmol Retina*. 2024 Jun;8(6):527-536. doi: 10.1016/j.oret.2024.01.004. Epub 2024 Jan 6. *Ophthalmol Retina*

Clinical Features Related to OCT Angiography Artifacts in Patients with Diabetic Macular

Edema, Tamer Kaderli S, Piccoli G, Limoli C, Ginelli S, Caboni S, Brotto L, Torti E, O'Toole L, Nucci P, Vujosevic S. *Ophthalmol Retina*. 2024 Aug;8(8):813-822. doi: 10.1016/j.oret.2024.02.017. Epub 2024 Mar 4. *Ophthalmol Retina*

Spine

Does Spinal Cord Type Predict Intraoperative Neuro-Monitoring Alerts in Scoliosis Correction Surgery? A Systematic Review and Meta-Analysis of Operative and Radiologic Predictors

Al-Naseem AO, Al-Naseem AO, Cawley DT, Aoude A, Catanzano AA Jr, Abd-El-Barr MM, Sharma A, Shafafy R. *Global Spine J*. 2024 Sep;14(7):2170-2182. doi: 10.1177/21925682241237475. Epub 2024 Mar 1. *Global Spine J*

An Assessment of the World's Contribution to Spine Trauma Care: A Bibliometric Analysis of Classifications and Surgical Management; An AO Spine Knowledge Forum Trauma Initiative

Chhabra HS, Phadke V, Manghwani J, El-Sharkawi M, Butler JS, Benneker LM, Vialle E, Hazenbiller O, Bransford R. *Global Spine J*. 2024 Apr;14(3):1061-1069. doi: 10.1177/21925682231205104. Epub 2023 Oct 17. *Global Spine J*

Natural History of Intradiscal Vacuum Phenomenon and its Role in Advanced Disc Degeneration

Cawley DT, Simpkin A, Abraham E, Doyle T, Elsheikh N, Fallon J, Habash M, Phua RJ, Langille J, Matini E, McNamee C, Mohamed F, Nic Gabhann C, Noorani A, Oh J, O'Reilly P, O'Sullivan D, Devitt A. *Spine (Phila Pa 1976)*. 2024 Aug 15;49(16):1130-1136. doi: 10.1097/BRS.0000000000004945. Epub 2024 Feb 2. *Spine (Phila Pa 1976)*

Pathology

The role of multidisciplinary team meeting histopathology review and its impact on revised reports: Analysis of a national quality improvement program, O'Connor E, Treacy A, Mitchell A, Swan N. *Am J Clin Pathol*. 2024 Jun 3;161(6):579-585. doi: 10.1093/ajcp/aqad183. *Am J Clin Pathol*

The role of multidisciplinary team meeting histopathology review and its impact on revised reports: Analysis of a national quality improvement program

Eoghan O'Connor 1, Ann Treacy 2, Aine Mitchell 1, Niall Swan 3, O'Connor E, Treacy A, Mitchell A, Swan N. *Am J Clin Pathol*. 2024 Jun 3;161(6):579-585. doi: 10.1093/ajcp/aqad183. PMID: 38330196. *American Journal of Clinical Pathology*

Urology

Bilateral orchidopexy for intermittent testicular torsion

Hegarty PK, Kalantar M, Hegarty PA, Zafirakis H, Monahan JE. *BJUI Compass*. 2024 Sep 20;5(11):1017-1022. doi: 10.1002/bco2.439. eCollection 2024 Nov. *BJUI Compass*

Neurology

POLR3A-related disorders: expanding the clinical phenotype

McKenna MC, O'Connor A, Lockhart A, Bogdanova-Mihaylova P, Brett F, Langan Y, Meaney J, Costigan D, Doherty CP, Bede P, Murphy SM, Hutchinson S. *J Neurol*. 2024 Jun;271(6):3635-3638. doi: 10.1007/s00415-024-12265-9. Epub 2024 Feb 27. *J Neurol*

Geriatric Medicine

Nutritional care in older adults: are we doing everything? An expert opinion review

Sanchez-Garcia E, Cruz-Jentoft AJ, Ravasco P, Suominen M, Pitkälä PK. *Curr Med Res Opin*. 2024 Sep;40(9):1563-1576. doi: 10.1080/03007995.2024.2380007. Epub 2024 Aug 1. *Curr Med Res Opin*

Other

The correlation between sub-epidermal moisture measurement and other early indicators of pressure ulcer development – A prospective cohort observational study.

Part 1. The correlation between sub-epidermal moisture measurement and ultrasound, *Wilson HJE, Patton D, Budri AMV, Boland F, O'Connor T, McDonnell CO, Rai H, Moore ZEH.* Int Wound J. 2024 Mar;21(3):e14732. doi: 10.1111/iwj.14732. Int Wound J

Sustainable surgical practices: A comprehensive approach to reducing environmental impact, *McNamee C, Rakovac A, Cawley DT.* Surgeon. 2024 Oct;22(5):253-259. doi: 10.1016/j.surge.2023.08.007. Epub 2023 Sep 15. Surgeon

The correlation between sub-epidermal moisture assessment and other early indicators of pressure ulcer development: A prospective cohort observational study. **Part 2. The correlation between sub-epidermal moisture assessment, temperature, epidermal hydration and pain,** *Wilson HJE, Patton D, Budri AMV, Boland F, O'Connor T, McDonnell CO, Rai H, Moore ZEH.* Int Wound J. 2024 Oct;21(10):e70058. doi: 10.1111/iwj.70058. Int Wound J

Clinical evaluation of real-time artificial intelligence provision of expert representation in indocyanine green fluorescence angiography during colorectal resections, *Singaravelu A, Mc Entee PD, Hardy NP, Khan MF, Mulsow J, Shields C, Cahill RA.* Int J Surg. 2024 Dec 1;110(12):8246-8249. doi: 10.1097/JS9.0000000000002136. Int J Surg

Characterisation and mitigation of gas leaks at laparoscopy: an international prospective, multi-center cohort clinical trial, *Nolan K, Khan MF, Riva P, Kearns E, Reitano E, Irving H, Perretta S, Dallemagne B, Cahill RA.* Surg Endosc. 2024 Jan;38(1):426-436. doi: 10.1007/s00464-023-10536-6. Epub 2023 Nov 20. Surg Endosc

PyDAP: Automated dental OPG beam area measurement using python and raspberry Pi camera, *Michael Murray, McCavana J, Eamon Loughman.* Phys Med. 2024 Apr;120:103338. doi: 10.1016/j.ejmp.2024.103338. Epub 2024 Mar 29. Phys Med






Scan the QR code to watch a review of 2024 highlights at Mater Private Network



www.materprivate.ie

